Delivery Order SPE2DR25D2206-SPE2DR26F9DD4
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $3,159.90 to AmerisourceBergen Drug Corp for the supply of Zepbound 15 mg/0.5 ml pens on October 20, 2025. This is a firm fixed price, competitively awarded delivery order with an ultimate completion date of October 21, 2025. The contract will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound is a semaglutide-based weight management medication indicated for chronic weight...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $30,103.40 for Zepbound 7.5 mg/0.5 mL pens on July 21, 2025, with an ultimate completion date of July 22, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania location. Zepbound is a semaglutide-based medication indicated for weight management and represents part of the pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $28,626.73 to AmerisourceBergen Drug Corp for the supply of Zepbound 15 mg/0.5 mL pens on November 18, 2025, with completion scheduled for November 19, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Zepbound is a weight management medication containing semaglutide, reflecting the federal...
- The Defense Logistics Agency awarded a $13,859.30 delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 mL pens on July 30, 2025, with an ultimate completion date of July 31, 2025. This competitively awarded, firm fixed-price contract includes no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Zepbound is a semaglutide-based medication used for weight management, representing part of the...
- The Defense Logistics Agency awarded a $46,152.35 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound 2.5 mg/0.5 mL pens on October 28, 2025, with an ultimate completion date of October 29, 2025. Zepbound is a brand-name semaglutide product indicated for weight management in eligible patients. This delivery order was issued without set-aside designation, meaning it was competitively awarded through open competition. The place of performance is listed as...
- The Defense Logistics Agency awarded a delivery order valued at $2,240.96 to AmerisourceBergen Drug Corp for the supply of Zepbound 10 mg/0.5 mL pen injections on November 4, 2025, with completion scheduled for November 5, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound is a semaglutide-based medication used for weight management, and...
- The Defense Logistics Agency awarded a $66,148.76 delivery order to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of Zepbound 15 mg/0.5 mL pen injections. This is a firm fixed price, non-set-aside contract with an ultimate completion date of August 7, 2025, and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. Zepbound is a semaglutide-based medication indicated for weight management, reflecting the agency's procurement needs for...
- The Defense Logistics Agency awarded a $3,117.26 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 12.5 mg/0.5 mL pen injectors on November 18, 2025, with completion scheduled for November 19, 2025. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.999 billion and extending through December 2026. The contract was competitively awarded...
- The Defense Logistics Agency awarded a delivery order valued at $13,306.04 to AmerisourceBergen Drug Corp for the supply of Zepbound 2.5 mg/0.5 mL pens on August 11, 2025, with an ultimate completion date of August 12, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Zepbound is a semaglutide injection used for weight management in adults with obesity or...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,262.71 to AmerisourceBergen Drug Corp for the supply of Zepbound 10 mg/0.5 mL pens on September 23, 2025, with an ultimate completion date of September 24, 2025. This firm fixed-price delivery order represents a non-competitive set-aside contract and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Zepbound is a semaglutide-based pharmaceutical product used for weight...
- SPE2DR25D2206Indefinite Delivery Contract
- SPE2DR25D2206-SPE2DR26F9DD4Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $11,389.64 to AmerisourceBergen Drug Corp for the supply of Zepbound 15 mg/0.5 mL pens on November 24, 2025, with an ultimate completion date of November 25, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound is a semaglutide-based medication used for weight management in adults with obesity or overweight conditions. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX and valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor and critical federal medical vendor, AmerisourceBergen supplies a comprehensive range of pharmaceutical products and medical commodities to support military healthcare programs and other government healthcare systems, including the Defense Health Agency and U.S. Coast Guard. The company's substantial federal contract portfolio demonstrates its capability to fulfill complex medical procurement requirements across multiple therapeutic domains on a competitive basis.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.4k | 11/23/25 |